Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases

Journal of the National Cancer Institute

Volumn 89, Issue 11, 1997, Pages 790-795

  Durand Zaleski, Isabelle ^a   Roche, Béatrice ^a   Buyse, Marc ^b   Carlson, Robert ^c   O'Connell, Michael J ^d   Rougier, Philippe ^e   Chang, Alfred E ^f   Sondak, Vernon K ^f   Kemeny, Margaret M ^g   Allen Mersh, Tim G ^h   Fagniez, Pierre Louis ^a   Le Bourgeois, Jean Paul ^a   Piedbois, Pascal ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^c STANFORD UNIVERSITY   (United States)

^d MAYO CLINIC   (United States)

^e Grp d'Etud Rech Tumeurs H   (France)

^f UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^g NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^h CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLOXURIDINE;

ARTICLE; CANCER CHEMOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LIVER METASTASIS; MAJOR CLINICAL STUDY;

EID: 0030965888     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.11.790     Document Type: Article

References (31)

1. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis Group In Cancer. J Natl Cancer Inst 1996;88:252-8.
2. Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culane M, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987;206:685-93.
3. Hohn DC, Stagg RJ, Friedman MA, Hannigan JF Jr, Rayner A, Ignoffo RJ, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 1989;7:1646-54.
4. Kemeny MM, Goldberg D, Beatty JD, Blayney D, Browning S, Doroshow J, et al. Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. Cancer 1986;57:492-8.
5. Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987;107:459-65.
6. Martin JK Jr, O'Connell MJ, Wieand HS, Fitzgibbons RJ Jr, Mailliard JA, Rubin J, et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 1990; 125:1022-7.
7. Rougier P, Laplanche A, Huguier M, Hay JM, Ollivier JM, Escat J, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992;10:1112-8.
8. Allen-Mersh TG, Earlam S, Fordy C. Abrams K, Houghton J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 1994;344:1255-60.
9. Allen-Mersh TG. Improving survival after large bowel cancer [editorial]. BMJ 1991;303:595-6.
10. Cole BF. Evaluating the clinical and economic trade-offs of hepatic arterial infusion [editorial]. J Natl Cancer Inst 1996;88:223-4.
11. Economic analysis of health care technology. A report on principles. Task Force on Principles for Economic Analysis of Health Care Technology. Ann Intern Med 1995;123:61-70.
12. Drummond M, Stoddart G, Torrance G. Methods for economic evaluation of health care programmes. Oxford: Oxford University Press, 1989:18-34, 74-83.
13. Drummond M. Cost-effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status? [editorial] Health Econ 1992;1:85-92.
14. Sculpher M, Henderson R, Buxton M, Pocok S, Parker J, Joy M, et al. Health service costs of coronary angioplasty bypass surgery: the Randomized Intervention Treatment of Angina (RITA) Trial. Lancet 1994;344:927-30.
15. Anderson DR, O'Brien BJ, Levine MN, Roberts R, Wells PS, Hirsh J. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med 1993;119:1105-12.
16. Midgette AS, Wong JB, Beshansky JR, Porath A, Fleming C, Pauker SG. Cost-effectiveness of streptokinase for acute myocardial infarction: a combined meta-analysis and decision making of the effects of infarct location and of likelihood of infarction. Med Decis Making 1994;14:108-17.
17. Robinson R. Cost-effectiveness analysis. BMJ 1993;307:793-5.
18. Robinson R. Economic evaluation and health care. What does it mean? BMJ 1993;307:670-3.
19. Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995;87:417-26.
20. Findlay M. Cost analysis of palliative chemotherapy for patients with gastrointestinal malignancy [editorial]. Ann Oncol 1995;6:205-7.
21. Smith TJ, Hillner BE, Desch CE. Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J Natl Cancer Inst 1993;85:1460-74.
22. Hillner BE, Smith TJ, Desch CE. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results. JAMA 1992;267:2055-61.
23. Jonsson E. Economics in clinical cancer research: methodology and assessment. Biomed Pharmacother 1988;42:645-52.
24. Glimelius B, Hoffman K, Graf W, Haglund U, Nyren O, Pahlman L, et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995;6:267-74.
25. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146:473-81.
26. Zanon C, Grosso M, Zanon E, Veltri A, Alabiso O, Bazzan M, et al. Transaxillary access to effect local-regional chemotherapy with hepatic artery infusion (hepatic arterial infusion) for secondary or primitive hepatic tumors [abstract]. Ann Oncol 1996;7 Suppl:52.
27. The reform of healthcare systems. A review of seventeen countries. Paris: OECD Publications. 1994.
28. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306:752-5.
29. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. J Clin Oncol 1992;10:904-11.
30. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992;10:896-903.
31. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1994;12:960-9.